当前位置： SCI文献检索 > SWISS MEDICAL WEEKLY期刊下所有文献 > Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment.

Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment.

Abstract：

:The differential diagnosis for children with diabetes includes a group of monogenic diabetic disorders known as maturity-onset diabetes of the young (MODY). So far, six underlying gene defects have been identified. The most common subtypes are caused by mutations in the genes encoding the transcription factor HNF-1a (MODY 3) and the glycolytic enzyme glucokinase (GCK) (MODY 2). MODY 2 is the most benign form of diabetes as the threshold for glucose sensing is elevated resulting in mild, regulated hyperglycemia. MODY 2 may usually be treated with diet alone without risk of microvascular complications. Patients with MODY usually present as children or young adults. Genetic testing for MODY in diabetic subjects is often not performed because of the costs and its unavailability in Switzerland. We describe the impact of the genetic analysis for MODY 2 on diabetes management and treatment costs in a five-year-old girl. The patient and her diabetic mother were both found to have a heterozygous missense mutation (V203A) in the glucokinase gene. The five-year-old girl was started on insulin therapy for her diabetes but because her HbA1c remained between 5.8-6.4% (reference 4.1-5.7%) and her clinical presentation suggested MODY insulin was discontinued. She is now well controlled on a carbohydrate controlled diet regimen only. Omission of insulin treatment made regular blood glucose monitoring unnecessary and removed her risk of hypoglycemia. Costs for the genetic analysis were 500 Euro. At our centre costs for diabetes care of a patient with type 1 diabetes are approximately 2050 Euro/year compared to 410 Euro/year for the care of a patient with MODY 2. In addition, a diagnosis of MODY 2 may reassure patients and their families, as microvascular complications are uncommon. Thus there are both health and financial benefits in diagnosing MODY 2. We recommend genetic testing for MODY 2 in clinically selected patients even though this analysis is currently not available in Switzerland and costs are not necessarily covered by the health insurances.

journal_name

Swiss Med Wkly

journal_title

Swiss medical weekly

authors

Schnyder S,Mullis PE,Ellard S,Hattersley AT,Flück CE

doi

2005/23/smw-11030

keywords:

subject

Has Abstract

pub_date

2005-06-11 00:00:00

pages

352-6

issue

23-24

eissn

1424-7860

issn

1424-3997

pii

smw-11030

journal_volume

135

pub_type

杂志文章

在线工具

Genetic testing for glucokinase mutations in clinically selected patients with MODY: a worthwhile investment.